- Daiichi Sankyo, Inc. (Bernards, NJ)
- …unmet medical needs of people globally by leveraging our world-class science and technology . With more than 120 years of scientific expertise and a presence in ... internal senior stakeholders to assess, develop, implement and drive execution of Strategic Sourcing activities (for both US and Global), from Request for Proposal… more
- Merck & Co. (Rahway, NJ)
- …perspectives from various sources to meet customer and stakeholder needs.Build strategic partnerships with manufacturing sites and partner groupsTeam Management ... Technology Organization. This position is responsible for providing strategic program leadership, technical expertise, and project management in the scale-up,… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Daiichi Sankyo, Inc. (Bernards, NJ)
- …unmet medical needs of people globally by leveraging our world-class science and technology . With more than 120 years of scientific expertise and a presence in ... system. Maintain the highest standards in payroll record management by introducing advanced systems and practices that improve both security and efficiency in… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... and commercialize a chimeric antigen receptor (CAR) T-cell therapy. This innovative strategic partnership is designed to combine the strengths and expertise… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Daiichi Sankyo, Inc. (Bernards, NJ)
- …may impact multiple organizational units or project teams. This position has advanced skills in technology systems, content creation, word processing software ... of people globally by leveraging our world-class science and technology . With more than 120 years of scientific expertise...for R&D PV QA and track business objectives through partnership with the QA leadership team . Position is… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Daiichi Sankyo, Inc. (Bernards, NJ)
- …unmet medical needs of people globally by leveraging our world-class science and technology . With more than 100 years of scientific expertise and a presence in ... and tactical plan as part of the US Brand Strategic Plan and leads the execution of the activities...medical education activities related to the compound data. In partnership with Medical Intelligence and Congress Planning leads, communicates… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise ... developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
